Medicine & Life Sciences
Squamous Cell Carcinoma of Head and Neck
100%
Head and Neck Neoplasms
64%
Neoplasms
26%
Immunotherapy
23%
pembrolizumab
20%
Chemoradiotherapy
19%
Survival
19%
Induction Chemotherapy
16%
Squamous Cell Carcinoma
15%
Oropharyngeal Neoplasms
14%
Progression-Free Survival
13%
Biomarkers
13%
Therapeutics
12%
Radiotherapy
10%
durvalumab
10%
Mutation
9%
Bevacizumab
9%
Squamous Cell Neoplasms
9%
Papillomaviridae
9%
enzastaurin
9%
Malignant Mesothelioma
8%
Fluorouracil
8%
Carboplatin
8%
ErbB Receptors
8%
Clinical Trials
8%
Hydroxyurea
8%
Re-Irradiation
8%
T-Lymphocytes
7%
Ligands
7%
tremelimumab
7%
Phosphatidylinositol 3-Kinases
7%
1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
7%
Drug Therapy
6%
Mouth
6%
ARQ 197
6%
Tumor Burden
6%
Transcriptome
6%
Hepatocyte Growth Factor
6%
Cell Line
5%
High-Throughput Nucleotide Sequencing
5%
Safety
5%
Maximum Tolerated Dose
5%
Proto-Oncogene Proteins c-met
5%
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
5%
Platinum
5%